Stephen V. Liu, MD
Stephen V. Liu, MD, is a thoracic medical oncologist and an Associate Professor of Medicine at Georgetown University. He is the Director of Thoracic Oncology and the Head of Developmental Therapeutics at the Georgetown University Lombardi Comprehensive Cancer Center. He is also co-host of the official IASLC podcast, Lung Cancer Considered.
Articles by Stephen V. Liu, MD
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
The panel discussed advancements in the field, including results from a study of lurbinectedin plus atezolizumab for SCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
Dr. Liu weighs in on the CheckMate 816 data presented at the 2025 ASCO Annual Meeting.
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
Dr. Liu unpacks key questions in the field, and the research that could address them.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.